文献速递头颈与中枢神经肿瘤

神经干细胞递送溶瘤腺病毒治疗新诊断恶性胶质瘤的首次人体1期剂量递增试验

Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.
PubMed 文献 · Lancet Oncol · 2021-06-29

这项首次人体、开放标签、1期剂量递增试验采用3+3设计,评估神经干细胞递送溶瘤腺病毒NSC-CRAd-S-pk7在新诊断高级别胶质瘤患者中的安全性和活性。

要点

  • NSC-CRAd-S-pk7治疗可行且安全,未达到正式剂量限制性毒性。

核心结论

  • NSC-CRAd-S-pk7治疗在新诊断高级别胶质瘤患者中可行且安全。
  • 免疫学和组织病理学发现支持继续开展2/3期临床试验。

研究设计与样本

  • 首次人体、开放标签、1期剂量递增试验,采用3+3设计。
  • 招募新诊断、组织学确诊的高级别胶质瘤(WHO III或IV级)患者。
  • 神经外科切除后,将NSC-CRAd-S-pk7注射到切除腔壁。
  • 12例患者纳入安全性分析,其中11例(92%)为胶质母细胞瘤,1例(8%)为间变性星形细胞瘤。
  • 中位随访18个月(IQR 14-22)。

主要发现

  • 未达到正式剂量限制性毒性,无治疗相关死亡。

关键数值与推荐

  • 治疗后10-14天内开始替莫唑胺和放疗。

临床怎么用

  • 对于新诊断高级别胶质瘤,切除后瘤腔壁注射NSC-CRAd-S-pk7可行且安全。
  • 需注意避免意外注射入侧脑室,以防病毒性脑膜炎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malignant glioma is the most common and lethal primary brain tumour, with dismal survival rates and no effective treatment. We examined the safety and activity of NSC-CRAd-S-pk7, an engineered oncolytic adenovirus delivered by neural stem cells (NSCs), in patients with newly diagnosed high-grade glioma. METHODS: This was a first-in-human, open-label, phase 1, dose-escalation trial done to determine the maximal tolerated dose of NSC-CRAd-S-pk7, following a 3 + 3 design. Patients with newly diagnosed, histologically confirmed, high-grade gliomas (WHO grade III or IV) were recruited. After neurosurgical resection, NSC-CRAd-S-pk7 was injected into the walls of the resection cavity. The first patient cohort received a dose starting at 6·25 × 1010 viral particles administered by 5·00 × 107 NSCs, the second cohort a dose of 1·25 × 1011 viral particles administered by 1·00 × 108 NSCs, and the third cohort a dose of 1·875 × 1011 viral particles administered by 1·50 × 108 NSCs. No further dose escalation was planned. Within 10-14 days, treatment with temozolomide and radiotherapy was initiated. Primary endpoints were safety and toxicity profile and the maximum tolerated dose for a future phase 2 trial. All analyses were done in all patients who were included in the trial and received the study treatment and were not excluded from the study. Recruitment is complete and the trial is finished. The trial is registered with ClinicalTrials.gov, NCT03072134. FINDINGS: Between April 24, 2017, and Nov 13, 2019, 12 patients with newly diagnosed, malignant gliomas were recruited and included in the safety analysis. Histopathological evaluation identified 11 (92%) of 12 patients with glioblastoma and one (8%) of 12 patients with anaplastic astrocytoma. The median follow-up was 18 months (IQR 14-22). One patient receiving 1·50 × 108 NSCs loading 1·875 × 1011 viral particles developed viral meningitis (grade 3) due to the inadvertent injection of NSC-CRAd-S-pk7 into the lateral ventricle. Otherwise, treatment was safe as no formal dose-limiting toxicity was reached, so 1·50 × 108 NSCs loading 1·875 × 1011 viral particles was recommended as a phase 2 trial dose. There were no treatment-related deaths. The median progression-free survival was 9·1 months (95% CI 8·5-not reached) and median overall survival was 18·4 months (15·7-not reached). INTERPRETATION: NSC-CRAd-S-pk7 treatment was feasible and safe. Our immunological and histopathological findings support continued investigation of NSC-CRAd-S-pk7 in a phase 2/3 clinical trial. FUNDING: US National Institutes of Health.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Fares J, Ahmed AU, Ulasov IV, et al. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. Lancet Oncol. 2021. PMID: 34214495. doi:10.1016/S1470-2045(21)00245-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。